Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy

BACKGROUND: IL-33, found in high levels in participants with allergic disorders, is thought to mediate allergic reactions. Etokimab, an anti–IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies. METHODS: In this 6-week pl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Chinthrajah, Sharon, Cao, Shu, Liu, Cherie, Lyu, Shu-Chen, Sindher, Sayantani B., Long, Andrew, Sampath, Vanitha, Petroni, Daniel, Londei, Marco, Nadeau, Kari C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2019
Assuntos:
Clinical Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6948865/
https://ncbi.nlm.nih.gov/pubmed/31723064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.131347
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados